| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/20/2006 | EP1702914A1 Radio-opaque polymeric biomaterials |
| 09/20/2006 | EP1702910A1 Octahydronaphthalene derivative and medicine |
| 09/20/2006 | EP1702886A1 Porous silica having substance carried thereon |
| 09/20/2006 | EP1702627A1 Analgesic combination of sodium channel blockers with opioid antagonists |
| 09/20/2006 | EP1702626A1 Inhibitor for the formation of gammad-secretase complex |
| 09/20/2006 | EP1702625A1 Medicine containing genetically modified antibody against chemokine receptor ccr4 |
| 09/20/2006 | EP1702623A2 Use of interferon gamma for the treatment of cardiac hypertrophy |
| 09/20/2006 | EP1702621A2 Metal/Thiol biocides |
| 09/20/2006 | EP1702620A1 Immunopotentiator and method of enhancing immunological activity with the same |
| 09/20/2006 | EP1702619A2 Disinfecting and solubilizing steroid compositions |
| 09/20/2006 | EP1702618A2 Compositions and uses of ET743 in combination therapy for cancer treatment |
| 09/20/2006 | EP1702617A1 Cannabimimetic indole derivatives |
| 09/20/2006 | EP1702616A1 Compound artemisinin |
| 09/20/2006 | EP1702615A1 Glucose tolerance-improving agent |
| 09/20/2006 | EP1702614A1 Use of idebenone for the preparation of a topically-applied depigmentation composition and corresponding composition |
| 09/20/2006 | EP1702613A1 Preventive for the onset of liver cancer comprising quinone compound as the active ingredient |
| 09/20/2006 | EP1702612A1 Butylphtalide soft gel capsulte and its preparation procedure |
| 09/20/2006 | EP1702597A2 Drug delivery of phase changing formulation |
| 09/20/2006 | EP1702515A2 Fat or oil composition |
| 09/20/2006 | EP1702064A2 A biomimetic composition reinforced by a polyelectrolytic complex of hyaluronic acid and chitosan |
| 09/20/2006 | EP1702062A2 Differentiation of stem cells for therapeutic use |
| 09/20/2006 | EP1702056A2 Non-animal product containing veterinary formulations |
| 09/20/2006 | EP1701981A1 Cohesive gels from cross-linked hyaluronan and/or hylan,their preparation and use |
| 09/20/2006 | EP1701980A1 A simplified method to retrieve chitosan from acidic solutions thereof |
| 09/20/2006 | EP1701962A2 Rifamycin analogs and uses thereof |
| 09/20/2006 | EP1701960A1 Cysteine protease inhibitors |
| 09/20/2006 | EP1701959A1 Triazole derivatives as vasopressin antagonists |
| 09/20/2006 | EP1701958A2 Pyrrolo-pyrazine derivatives useful as cb1-modulators |
| 09/20/2006 | EP1701957A1 2-amino-o4-substituted pteridines and their use as inactivators of o6-alkylguanine-dna alkyltransferase |
| 09/20/2006 | EP1701956A1 Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 09/20/2006 | EP1701955A1 Arylalkenyl and arylalkynyl substituted imidazoquinolines |
| 09/20/2006 | EP1701954A1 N-substituted piperidine and piperazine derivatives |
| 09/20/2006 | EP1701952A1 Dutpase inhibitors |
| 09/20/2006 | EP1701951A2 Modulators of peripheral 5-ht receptors |
| 09/20/2006 | EP1701947A2 4-oxo-4,5-dihydro-furan-2-carboxylic and acid derivatives and methods of treatment of metabolic-related disorders thereof |
| 09/20/2006 | EP1701946A2 Derivatives of 1-piperazine- and 1-homopiperazine-carboxylates, preparation method thereof and use of same as inhibitors of the faah enzyme |
| 09/20/2006 | EP1701943A1 5-ht2 receptors modulators, their pharmaceutical compositions and their use for the treatment of cardiovascular and muscle diseases |
| 09/20/2006 | EP1701942A1 Non-nucleotide reverse transcriptase inhibitors |
| 09/20/2006 | EP1701941A1 Compounds for treatment of cell proliferative diseases |
| 09/20/2006 | EP1701940A1 2-(1h-indolylsulfanyl)-benzyl amine derivatives as ssri |
| 09/20/2006 | EP1701939A1 Anthraquinone compounds as anti cancer compounds |
| 09/20/2006 | EP1701934A2 DISUBSTITUTED CHALCONE OXIMES HAVING RAR(Gamma)-RETINOID RECEPTOR ANTAGONIST ACTIVITY |
| 09/20/2006 | EP1701933A1 Novel compounds |
| 09/20/2006 | EP1701932A1 Tolterodine, compositions and uses thereof, and preparation of the same |
| 09/20/2006 | EP1701742A2 Intranasal compositions comprising zolpidem |
| 09/20/2006 | EP1701741A2 Complexes having adjuvant activity |
| 09/20/2006 | EP1701735A2 Use of hydroxylated amino acids for treating diabetes |
| 09/20/2006 | EP1701727A1 Dutpase inhibitors |
| 09/20/2006 | EP1701726A2 Antimicrobial photodynamic therapy compound and method of use |
| 09/20/2006 | EP1701725A1 Methods and compositions |
| 09/20/2006 | EP1701724A2 Alkylamino, arylamino, and sulfonamido cyclopentyl amide modulators of chemokine receptor activity |
| 09/20/2006 | EP1701723A2 Colon cleansing composition and method |
| 09/20/2006 | EP1701722A1 N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy¨]pentoxy}benzamidine 2 methansulfonic acid salt |
| 09/20/2006 | EP1701721A1 Use of pilocarpine for hypoptyalism treatment |
| 09/20/2006 | EP1701720A1 Use of chp as an inhibitor of glutathione s-transferases and collagen iv |
| 09/20/2006 | EP1701719A1 Chp-gemcitabin combined agent and use thereof as anti-tumoural active substances |
| 09/20/2006 | EP1701718A2 Substituted melatonin derivatives, process for their preparation, and methods of use |
| 09/20/2006 | EP1701717A1 Method of treating elevated plasma homocysteine levels in esrd patients |
| 09/20/2006 | EP1701716A1 Antiaging composition |
| 09/20/2006 | EP1701715A1 Zeaxanthin formulations with additional ocular-active nutriente, for protecting eye health and treating eye disorders |
| 09/20/2006 | EP1701710A1 Microemulsions for pharmaceutical compositions |
| 09/20/2006 | EP1701708A2 Novel drug compositions and dosage forms of topiramate |
| 09/20/2006 | EP1701706A2 Novel drug compositions and dosage forms |
| 09/20/2006 | EP1701705A2 Enhanced absorption of modified release dosage forms |
| 09/20/2006 | EP1701702A1 Spray-congeal process using an extruder for preparing multiparticulate azithromycin compositions containing preferably a poloxamer and a glyceride |
| 09/20/2006 | EP1701700A1 Compositions comprising memantine and polyanionic polymers for administration to the eye |
| 09/20/2006 | EP1701699A2 Pharmaceutical compositions |
| 09/20/2006 | EP1701698A2 Directly compressible pharmaceutical composition for the oral admimistration of cci-779 |
| 09/20/2006 | EP1701697A2 Novel drug compositions and dosage forms of topiramate |
| 09/20/2006 | EP1599473B1 Imidazo 4,5-b quinoline-derivatives and their use as no-synthase inhibitors |
| 09/20/2006 | EP1554253A4 Imidazolium cxcr3 inhibitors |
| 09/20/2006 | EP1549755A4 Spliceosome mediated rna trans-splicing in stem cells |
| 09/20/2006 | EP1549624A4 Inhibitors of fatty acid amide hydrolase |
| 09/20/2006 | EP1497308B1 Method for producing steroid crystals, crystals obtained by said method and their use in pharmaceutical formulations |
| 09/20/2006 | EP1494648B1 Powder formulations suitable for inhalation |
| 09/20/2006 | EP1492513B1 Hfa-suspension formulations containing an anticholinergic |
| 09/20/2006 | EP1487835B1 Amides of acetic and propionic acids |
| 09/20/2006 | EP1458733B1 Silver salts of sucrose-octasulphate |
| 09/20/2006 | EP1450835B1 Compositions for the treatment of lupus |
| 09/20/2006 | EP1443940B1 Pharmaceutical composition based on micronized progesterone, preparation method and uses thereof |
| 09/20/2006 | EP1397148B1 Chromium/biotin treatment of dyslipidemia |
| 09/20/2006 | EP1392363B1 Use of mGLuR5 antagonists in the manufacture of a medicament in the treatment of Fragile X syndrome, Autism and Mental Retardation |
| 09/20/2006 | EP1368364B1 C2, 8-disubstituted adenosine derivatives and their different uses |
| 09/20/2006 | EP1366027B1 Combi-molecules having signal transduction inhibitory properties and dna damaging properties |
| 09/20/2006 | EP1353916B1 Pyrazole compounds useful as protein kinase inhibitors |
| 09/20/2006 | EP1343797B1 Macrolide antibiotics |
| 09/20/2006 | EP1343780B1 Piperazine derivatives for treatment of bacterial infections |
| 09/20/2006 | EP1315571A4 Concentric tubular centrifuge |
| 09/20/2006 | EP1280897B1 Regulation of nf-at interacting protein nip 45 variant |
| 09/20/2006 | EP1272530B1 Clathrate complexes formed by hyaluronic acid derivatives and use thereof as pharmaceuticals |
| 09/20/2006 | EP1272188B1 Use of egfr tyrosine kinase inhibitors for treating brest cancer |
| 09/20/2006 | EP1253145B1 Alkali metal salt of thiazolidine-2,4-dione derivatives |
| 09/20/2006 | EP1246841B1 Transcription factors containing two potential dna binding motifs |
| 09/20/2006 | EP1244627B1 Picolinic acid derivatives and their use as fungicides |
| 09/20/2006 | EP1200081B1 Use of escitalopram for the treatment of generalised anxiety disorder |
| 09/20/2006 | EP1171446B1 Macrolide antiinfective agents |
| 09/20/2006 | EP1161944B1 Drugs, foods and oral compositions containing stilbene-type compounds |
| 09/20/2006 | EP1158970B1 Combinations of formoterol and a tiotropium salt |
| 09/20/2006 | EP1156827B1 USE OF COMPOSITIONS COMPRISING CldC AS RADIOSENSITIZERS IN THE TREATMENT OF NEOPLASTIC DISEASES |
| 09/20/2006 | EP1079875B1 Cancer treatment by ultrapheresis removing compounds of less than 120,000 daltons |